Entrada Therapeutics (TRDA) Cash from Financing Activities (2020 - 2026)
Entrada Therapeutics' (TRDA) quarterly Cash from Financing Activities came in at $100000.0 in Q1 2026, down 71.43% year-on-year from $350000.0 in Q1 2025, and down 47.92% quarter-over-quarter from $192000.0 in Q4 2025.
Entrada Therapeutics (TRDA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $100000.0 for Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 71.43% year-over-year to $100000.0 in Q1 2026; TTM through Mar 2026 was $637000.0, a 99.38% decrease from a year earlier, with the FY2025 full-year figure at $887000.0, down 99.14% from the prior year.
- Cash from Financing Activities fell to $100000.0 in Q1 2026 per TRDA's latest filing, from $192000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $101.4 million in Q2 2024 and bottomed at -$11000.0 in Q3 2024.
- The 5-year median for Cash from Financing Activities is $337000.0 (2025), against an average of $7.4 million.
- Across the five-year window, Cash from Financing Activities jumped 38972.0% in 2023 and plunged 102.99% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at $358000.0 in 2022, then surged by 92.74% to $690000.0 in 2023, then soared by 103.19% to $1.4 million in 2024, then slumped by 86.31% to $192000.0 in 2025, then sank by 47.92% to $100000.0 in 2026.
- Per Business Quant, the three latest TRDA Cash from Financing Activities figures stand at $100000.0 (Q1 2026), $192000.0 (Q4 2025), and $8000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Entrada Therapeutics | 253.11 Mn | 253.11 Mn | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 192,000.00 |
| Dec 31, 2025 | 192,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 337,000.00 |
| Jun 30, 2025 | 337,000.00 |
| Mar 31, 2025 | 350,000.00 |
| Mar 31, 2025 | 350,000.00 |
| Dec 31, 2024 | 1.40 Mn |
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | -11,000.00 |
| Sep 30, 2024 | -11,000.00 |
| Jun 30, 2024 | 101.37 Mn |
| Jun 30, 2024 | 101.37 Mn |
| Mar 31, 2024 | 206,000.00 |
| Mar 31, 2024 | 206,000.00 |
| Dec 31, 2023 | 690,000.00 |
| Dec 31, 2023 | 690,000.00 |